Celldex Therapeutics, Inc. (CLDX) Q2 2014 Earnings Results

Celldex Therapeutics Misses on EPS — Stock Down 0.52%

Celldex Therapeutics reported a loss of $0.32 per share, slightly missing expectations. The stock reacted negatively, declining by 0.52%. The lack of revenue data and guidance may contribute to investor uncertainty about the company's future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.32	N/A	-4.58%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current financial performance. They emphasized their commitment to ongoing development efforts.

Management did not provide specific guidance for future performance.

The company is focused on advancing its pipeline despite current challenges.

Celldex Therapeutics Misses on EPS — Stock Down 0.52%

Key numbers

Management commentary

Celldex Therapeutics, Inc.

More earnings this week

Celldex Therapeutics Misses on EPS — Stock Down 0.52%

Key numbers

Management commentary